Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3F8 and GM-CSF for High-Risk Neuroblastoma
NCT02100930Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2014
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of anti-GD2 monoclonal antibody 3F8 in neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Therapeutic Response at 2 years and Complete Remission at 2 years. Started Mar 2014; status: completed.
02
Drugs
anti-GD2 monoclonal antibody 3F8
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02100930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02100930.